Know Cancer

or
forgot password

Evaluation of Nutrition and Metabolism in Breast Cancer Patients


N/A
18 Years
N/A
Open (Enrolling)
Female
Breast Cancer

Thank you

Trial Information

Evaluation of Nutrition and Metabolism in Breast Cancer Patients


Despite the increased success of novel anti-neoplastic therapies, breast cancer patients
receiving chemotherapy develop unfavourable changes in body composition, including lean
tissue loss and fat gains (1,2). These detrimental changes associate with poor quality of
life (3,4) and may lead to treatment complications (5,6) during the cancer trajectory. In
non-malignant populations, fat gain and muscle loss associate with increased risk of
cardiovascular disease and diabetes (7). Cancer survivors who gain fat and lose lean mass
are not only predisposed to these diseases but also have an increased risk of cancer
recurrence (3). Proper nutrition as well as exercise can independently improve metabolic
profiles (i.e. immune function, lipid and glucose metabolism) and overall health outcomes in
non-malignant populations (7-9). While exercise has enhanced quality of life in breast
cancer patients (4), overall nutritional needs and the metabolic benefits of exercise are
unclear in this patient group. Understanding the effects of nutrition and exercise
interventions in breast cancer patients will form the basis for future studies and programs
that integrate nutrition, exercise, and metabolism to reduce cancer recurrence and other
morbidities in survivorship. This study will examine the effects of nutrition and exercise
intervention on body composition and metabolism in recently diagnosed breast cancer
patients.


Inclusion Criteria:



- Females 18 years old or older

- Recent diagnosis of breast cancer and up to 4 weeks following the first cycle of
chemotherapy or up to the first 4 weeks of radiation therapy

- Clinical Stages I-IIIa

- Able to communicate freely in English

- Have sufficient cognitive ability to participate and provide informed consent

Exclusion Criteria:

- Any known diagnosis of cardiovascular disease and thyroid disease that is not
currently managed with medication or other therapies

- Any known diagnosis of diabetes or HIV

- Pre-existing injuries or health conditions that prevents the patient's safe
participation in exercise

- Any previous diagnosis of cancer within the last 5 years (other than carcinoma in
situ)

- Fasting glucose >7.0 mM at baseline of the study

- Pregnant individuals will be excluded from this study

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Outcome Measure:

Change in glucose parameters from baseline

Outcome Description:

Oral glucose tolerance tests will be performed at each assessment. Changes from baseline will be measured.

Outcome Time Frame:

Baseline, 8 weeks, 16 weeks

Safety Issue:

No

Principal Investigator

Marina Mourtzakis, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Waterloo

Authority:

Canada: Ethics Review Committee

Study ID:

17215

NCT ID:

NCT01542216

Start Date:

February 2012

Completion Date:

September 2015

Related Keywords:

  • Breast Cancer
  • Breast Neoplasms

Name

Location